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1. Introduction
Since several decades ago chronic pain understanding has become in one of the most intriguing
challenges for health professionals (rheumatologists, psychologists, physiotherapists, anaes‐
thesiologists, pharmacologists, etc). Different reasons are behind that traditionally poor
knowledge about the etiology, mechanisms and treatment of chronic pain. Pain has been very
often considered as a peripheral entity in which peripheral causes, such as inflammation and
structural joint damage, have been only explored. Thus, difficulties to explain painful symp‐
tomatology associated to chronic pain patients, such as the great discordance between pain
complaints or severity and their supposed peripheral causes, have lead to the development of
investigations to advance in the knowledge of pain mechanisms in chronic pain diseases (p.e.,
non-inflammatory conditions), such as it occurs in fibromyalgia (Buskila, 2009). These studies
have highlighted both the important role of central pain-processing mechanisms and its
evidently multifactorial status (Lee et al., 2011; Schweinhardt et al., 2008).
Fibromyalgia (FM) constitutes a chronic syndrome mainly characterized by the presence of
widespread and diffuse pain (Fan, 2004). Traditionally, FM diagnosis has been only established
by the presence of widespread pain during at least three months and tenderness to palpation
at specific locations (the so-called ‘tender points’) following the American College of Rheu‐
matology criteria (ACR, Wolfe et al., 1990). refer to 18 places symmetrically distributed at both
sides of the body where patients feel pain when a weak pressure is applied on them with the
thumb of the examiner (lower than 4kg/cm2, see Figure 1). Currently, this syndrome is affecting
between 2-4% of population (between 80 and 90 percent of patients diagnosed with FM are
© 2013 Mercado et al.; licensee InTech. This is an open access article distributed under the terms of the
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women) being one of the most common causes of pain and disability. However, the biological
bases for the clinical characteristics of FM remain elusive (Martínez-Lavin, 2004; Montoya et
al., 2005; Vierck, 2006). Studies have focused particularly on the mechanisms underlying pain
perception, and central signals processing. FM patients refer two kinds of somatic sensations:
a) enhanced pain sensitivity to painful stimulation (hyperalgesia) and b) a painful response to
a normally innocuous stimulus (allodynia). Central augmentation mechanisms underlying
this amplified pain perception have been investigated using advanced imaging techniques that
aim to localize and describe alterations in specific areas of the brain. Indeed, scientific evidence
suggests that central abnormalities in the processing of pain signals seem to be responsible of
such altered pain manifestations (diffuse hyperalgesia and allodynia) in FM (Staud et al.,
2004; Thieme et al., 2005).
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Figure 1. Bilateral tender point locations for the traditional ACR diagnosis criteria for Fibromyalgia (adapted from
Wolfe et al., 1990). (a) ANTERIOR VIEW: 1. Low cervical: the anterior aspects of the intertransverse spaces at C5-C7, 2.
Second rib: the second costochondral junctions, lateral to the junctions on upper surfaces, 3. Lateral epicondyle: 2cm
distal to the epicondyles, 4. Knee: the medial fat pad proximal to the joint line. (b) POSTERIOR VIEW: 5. Occiput: the
suboccipital muscle insertions, 6. Trapezius: the midpoint of the upper border, 7. Supraspinatus: above the scapula
spine near the medial border, 8. Gluteal: upper outer quadrants of buttocks in anterior fold of muscle, 9. Greater tro‐
chanter: posterior to the trochanteric prominence.
Additionally, people with FM frequently experience a great amount of other accompanying
symptoms apart from pain, such as physical complaints (stiffness, fatigue, sleep problems),
affective disorders (anxiety or depression) and cognitive dysfunctions (failures in memory,
attention and concentration). In fact, cognitive failures represent one of the most important
complaints of these patients, recently denominated as fibrofog (Glass, 2010), leading to produce
even greater functional impact than pain itself (Glass, 2009). Based on growing evidence from
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neuropsychological and neuroimaging studies, ACR criteria have been recently modified
including the cognitive dysfunction and affective disturbances, among other symptoms, as
key factors for FM diagnosis (Wolfe et al., 2010). These findings, along with the lack of
peripheral signs of inflammation to account for pain, support the hypothesis that FM is a
syndrome characterized by an abnormal processing of information at the level of central
nervous system. Therefore, psychoneurobiologic dysfunctions seem to be crucial for trying to
explain this multifactorial and still not fully understood clinical condition (Lee et al., 2011;
Schweinhardt et al., 2008), but also to give response, at least partially, to the appearance and
maintenance of both pain-related and cognitive symptomatology. In the following review, we
will try to describe what is currently known about the cerebral mechanisms in pain processing,
the neural correlates of cognitive dysfunction and the pathogenesis of FM, with special
attention to the genetic basis.
2. Cerebral pain processing in fibromyalgia
Fibromyalgia is considered a chronic pain syndrome which cause (still remain elusive) does
not have been found in localized lesions, inflammatory processes or damage to the joints,
muscles or other tissues. Experimental evidence indicates that pain processing abnormalities
leading to maintenance of pain showed by these patients (e.g., hyperalgesic states) could be
due to both central sensitization mechanisms and specific defects in central pain processing
related to the loss of normal activity of descending pain-inhibitory (e.g., serotonin-norephi‐
nephrine-opioidergic) pathways (Ceko et al., 2012; Lee et al., 2011). Central sensitization
related to diffuse hyperalgesia and allodynia is functionally linked to central nervous changes
caused by the release of different excitatory neurotransmitters such as serotonin, substance P
or glutamate, among others. Through their action on specific receptors (e.g., NMDA) those
neurotransmitters might produce enhanced and amplified responses at central nervous level
(Woolf, 2004). Specifically, central sensitization can also produce an augmentation of receptive
fields in neurons belonging to spinal cord and peripheral fibers. Other neurophysiological
indices found in FM patients have involved elevated levels of substance P and serotonin
metabolites in cerebrospinal fluid compared with healthy people (Russell et al., 1994; Russell
et al., 1992), along with a diminished level of neurotransmitters, which dampen pain sensitivity
response (e.g., norepinephrine) suggesting again defects in central pain processing (Russell et
al., 1992). Behaviourally, the phenomenon of central sensitization is characterized by lower
thresholds in pain perception, pain tolerance and by an enhancement of noxious sensations as
a consequence of repeated stimulation, as it occurs in temporal summation (Staud et al.,
2003). Additionally, whereas the activation of NMDA receptor channels produces central
sensitization, the administration of NMDA receptor antagonists such as ketamine reduces
significantly pain perception and facilitates the inhibition of hyperalgesia indices (i.e.,
temporal summation) in FM patients (Price et al., 2002; Graven-Nielsen et al., 2000). Neuroi‐
maging studies have demonstrated the presence of an augmented activation pattern of pain
processing involving several cortical and subcortical regions in FM (Gracely et al., 2002). This
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augmented pain processing pattern resulted in response to the same perceived intensity of
painful stimulation compared to control participants (Gracely et al., 2002; Cook et al., 2004).
Pain descending inhibitory pathways start from different cerebral levels localized on the
brainstem, bulbar region, diencephalic structures and cortical areas. These pathways constitute
one of the most important mechanisms involved in the pain perception modulation of sensory
information in the dorsal horn of spinal cord. Experimental evidence has described defects in
those pain inhibitory pathways leading to a loss of descending endogenous analgesia and the
maintenance and enhancement of painful sensations in patients with FM (Julien et al., 2005).
These results have been found using different types of acute noxious stimulation. Staud and
colleagues (2003) highlighted the presence of diminished pain inhibitory mechanisms in
response to hot water in a sample of women with and without FM. Previous studies applying
tonic thermal stimulation and by using a tourniquet to produce ischemic pain showed evidence
for the defects in descending inhibitory pain activity in FM (Lautenbacher et al., 1997; Kosek
et al., 1997). In the same line, diminished periaqueductal gray responses to heat stimulation
have been reported in these patients when it was compared with the activity of healthy
participants (Cook et al., 2004). Periaqueductal gray region (PGR) has been described as an
important structure involved in both ascending and descending pain processing signals (Stahl,
2009). Descending projections from PGR to dorsolateral pontine structures act inhibiting pain
signals from peripheral afferent neurons in the dorsal horn of the spinal cord through the
release of noradrenaline and serotonin neurotransmitters. Thus, the observed lack of activation
within PGR in FM could lead to a loss of descending analgesia enhancing chronic responses
of hyperalgesia in these patients (Herrero et al., 2000). Exposed findings demonstrate the main
role of abnormalities in central mechanisms as an important key to understand chronic pain
in the FM syndrome (Abeles et al., 2007; Bennett, 2005; Lee et al., 2011).
2.1. Morphological brain changes associated with abnormal pain processing in fibromyalgia
Experimental evidence focused on the study of brain areas involved in the processing of
painful stimulation has revealed that chronic pain patients show an abnormal activation
pattern at specified brain regions (e.g., Kwiatek et al., 2000). Neuroimaging research and its
application to the study of pain, has facilitated the identification of a brain network involved
in pain processing that has been denominated as ‘pain matrix’, comprised, among others, by
different cortical and subcortical regions: for example, somatosensory regions, insular areas
and anterior cingulated cortices (ACC) (Bushnell et al., 2005; Tracey &Mantyh, 2007). Although
recently the referred pain matrix has been functionally redefined not only as a pain processing
network but also as salience detection system (Iannetti et al., 2010; Legrain et al., 2011; Tracey
& Johns, 2010), the role played by somatosensory cortices and other cortical regions, such as
posterior parietal cortex or prefrontal areas in the processing of nociceptive signals and in the
affective/cognitive modulation processes of pain perception, has been extensively documented
(Lorenz et al., 2003; Peyron et al., 2000; Rolls et al., 2003; Sawamoto et al., 2000; Singer et al.,
2004; Wiech et al., 2008). For instance, attentional modulations on pain perception have been
seen in the increase and/or decrease of activations within insula and ACC (Valet et al., 2004;
Wiech et al., 2005).
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Chronic pain diseases are commonly characterized by an abnormal functioning when painful
events are processed and as a consequence of it, chronic pain has been understood as an altered
perceptual state (Apkarian et al., 2005). Nevertheless, chronic pain is also defined as a dysfunc‐
tional condition derived from the appearance of structural brain changes that become more
generalized as a function of the years suffering from pain (Baliki et al., 2011). Such changes could
cause a dysfunctional neural  reorganization affecting brain dynamics (Baliki  et  al.,  2008;
Tagliazucchi et al., 2010). Evidence accumulated from the last years through the use of different
brain imaging methodologies supports the presence of changes in the brain of FM patients (i.e.,
structural and functional changes) (García-Campayo et al.,  2010; Gracely et al.,  2011),  al‐
though such changes are heterogeneous and a unique interpretation about its clinical mean‐
ing remains still unclear. Altered brain morphology was reported by voxel-based morphometry
(VBM) studies showing that FM patients had less grey matter density than healthy subjects in
several brain regions including insula and ACC (Kuchinad et al., 2007). However, grey matter
increase in other cerebral areas belonging to the somatosensory system, such as the Striatum or
in those other ones involved in the cognitive modulation of pain (i.e., Orbitofrontal Cortex-
OFC) have been seen in patients suffering from FM (Schmidt-Wilcke et al., 2007). Further
findings combining diffusion-tensor imaging (DTI) and VBM methodologies have described
not only a reduction in grey matter density in FM but also abnormalities in white matter
microstructure within thalamus and insular cortex, being highly correlated with the intensity
of main FM symptoms (Lutz et al., 2008). Specifically, patients showing higher pain intensity
scores were characterized by DTI measurements indicating changes within superior frontal
gyrus (SFG). Moreover, changes in SFG and ACC were positively correlated with increased
fatigue and self-perceived physical impairment. Affective symptoms defined by higher scores
in  posttraumatic  stress  scales  were  negatively  correlated  with  microstructural  changes
represented by values of fractional anisotropy (FA) in FM. In this line, Hsu and colleagues (2009)
reported decreased grey matter volume in the left anterior insula for patients with FM com‐
pared to healthy control participants. This difference in grey matter volume disappeared when
the presence of affective disorders in FM patients was controlled. Thus, grey matter volume
within this area was inversely correlated with scores in trait anxiety, highlighting the impor‐
tant role of affective disturbances in the explanation of these morphological brain changes. More
recent studies have documented that patients with FM syndrome show grey matter atrophy
within ACC, mid-cingulate Cortex (MCC) and insular cortex, but affective symptoms like
depression are not related to these grey matter changes (Robinson et al., 2011). Along with
emotional symptomatology, cognitive alterations in FM have been correlated with changes in
grey matter values (Luerding et al., 2008). They found that working memory performance in
FM patients was highly and positively correlated with decreased grey matter values within
medial prefrontal cortex (MPFC) and ACC, showing that cognitive deficits in FM are associat‐
ed with changes in brain morphology.
Therefore, mentioned brain abnormalities in the traditionally denominated pain matrix regions
might contribute to the alteration of pain processing in FM patients, but they could also affect
other domains such as cognitive and affective symptomatology. In fact, it has been proposed
that pain and cognitive impairment in FM may co-occur sharing underlying neural networks
(Luerding et al., 2008), and as a consequence of it, performance derived from carrying out a
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cognitive task when individual is in pain might decrease due to the availability of neural
resources is limited and they are invested in pain processing (Seminowicz and Davis, 2007).
Additionally, the presence of chronic pain along the years might contribute to the appearance
of changes in the brain leading to abnormal activation of brain regions that could exacerbate
pain itself and also disturb cognitive function in FM (Kuchinad et al., 2007). Although structur‐
al neuroimaging evidence supports the association of chronic pain in FM with grey matter
abnormalities, future investigations should be projected to confirm and extend these findings.
2.2. Functional brain changes associated with abnormal pain processing in fibromyalgia
Beyond morphological brain changes, functional imaging investigations have revealed
abnormal activation patterns at specific cerebral regions in FM patients (e.g., Cook et al.,
2004), however, these anomalies in pain processing are not always circumscribed to activation
of brain areas intimately or traditionally related to pain. It has been observed during different
experimental situations: in response to painful stimulation, when somatosensory (not painful)
information has to be processed and even during resting-state conditions. One of the first
neuroimaging studies conducted to investigate such issues demonstrated enhanced brain
activation in many regions (i.e., primary and secondary somatosensory cortex, ACC, insula)
for FM patients in response to similar levels of pressure stimulation to that one applied to
control subjects (Gracely et al., 2002). Moreover, when subjectively painful conditions were
established to be comparable (i.e., intensity of stimulation was significantly greater to healthy
people than patients for provoke a similar subjective level of pain perception) similar brain
activation patterns were found between both patients and control groups. These results
indicate that central sensitization defects could be explaining the presence of such augmented
activation pattern for painful signals in FM. More recent studies aimed to test the hypothesis
of central augmentation pain processing in FM have confirmed and extended those findings
(Maestú et al., 2013). Abnormal brain activation of different regions related to the affective/
motivational components of pain processing was found in patients with FM during a pain
situation induced by a small incision into the skin (Burgmer et al., 2009). Thus, enhanced
activations were observed within frontal and cingulated cortices, along with supplementary
motor areas. Such altered responses were especially prominent during the pain anticipation
period. Additionally, that altered temporal BOLD-signal pattern was found as specific for FM
patients when they were compared to other patients suffering from rheumatoid arthritis
(Burgmer et al., 2010). It leads to think that fronto-cingulated regions could play a key role as
central mechanisms of pain processing responsible to the maintenance and exacerbation of
chronic pain in FM.
Previous investigations had already given data about the role of cognitive, affective and social
factors on pain processing in FM. Neural responses to somatosensory stimuli can be modulated
by cognitive and emotional factors (Cook et al., 2004). Specifically, the catastrophyzing
thinking style has been associated with enhanced cerebral responses to pain. Cortical areas
involved in pain expectancy or pain-related attention (ACC, MPFC or dorsolateral prefrontal
cortex –DLPFC-) showed more intense activity in FM patients who scored high in catastroph‐
izing (Gracely et al., 2004). Affective conditions such as comorbid depression, seem to have
influence in the activation of amygdala, but not of somatosensory brain regions during pain
processing information (Giesecke et al., 2005). Event-related potentials (ERP) studies have also
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provided data demonstrating abnormal emotional modulation of brain processing in response
to somatosensory/non-painful stimuli (Montoya et al., 2005). Somatosensory components (i.e,
P50) displayed largest amplitudes when FM patients were introduced within a negative
emotional context created with unpleasant slides. The influence of the emotional context was
also described during the processing of painful stimulation (Montoya et al., 2004). At the same
time, the presence of significant others during the application of painful stimulation was found
as a social factor that diminish magnetic brain responses and subjective pain in FM patients
compared to control participants (Montoya et al., 2004). Other works have observed that FM
patients show a significant enhancement of brain activation within regions involved in the
emotional/cognitive aspects linked to pain processing as compared to control subjects, given
a painful stimulation (Burgmer et al., 2009). Indeed, larger activation within CCA and anterior
insula along with more persisting responses in insular cortex were found for FM patients as
well (Pujol et al., 2009). It supports the hypothesis that both affective/cognitive and social
factors may play a very important role for pain processing in patients with FM.
On the other hand, the role played by several neurotransmitters, such as dopamine or gluta‐
mate, which exerts their functions at the level of central neural system, has been also highlight‐
ed in the pathogenesis of FM and studied through the use of neuroimaging techniques (Harris,
2010; Stahl, 2009). Different genetic polymorphisms associated with the functional activity of
those neuromodulators have been documented (Ablin et al., 2008), as it will be extensively
described later. Evidence on altered levels of mentioned neurotransmitters within the brain of
patients with FM has recently reported (Harris et al., 2008; 2009). Dysregulation in levels of
glutamate, an excitatory neurotransmitter, has been found within the posterior insula of FM
patients being such altered levels associated with experimental pain (Harris et al., 2010). Higher
concentration levels of glutamate and glutamine were also detected within the amygdala
(Valdés et al., 2010) and posterior insula (Fayed et al., 2010). Patients group showed diminish‐
ed pain thresholds and high scores in pain and tenderness suggesting that neuronal hiperexcit‐
ability elicited by the presence of glutamate may lead to an augmented central pain processing.
With respect to other neurotransmitters, different investigations have indicated an abnormal
dopamine response to pain in FM (Wood et al., 2007b; Wood et al., 2009). It is known that
dopamine is a neurotransmitter involved in pain modulation, but whereas general popula‐
tion showed an increase of dopamine release when a painful stimulus was perceived FM patients
did not (Wood et al., 2007a). Thus, that deficiency in dopaminergic reactivity might have a
relevant impact on the development and maintenance of chronic pain in FM. In fact, some studies
have  shown  reduced  presynaptic  dopaminergic  activity  suggesting  that  such  disrupted
neurotransmission could prevent for natural analgesia in FM (Wood et al., 2007b). More recent
findings have associated alterations in dopaminergic neurotransmission with a decrease in grey
matter density within posterior cingulated cortex, ACC and parahippocampal gyri (Wood et
al., 2009). Therefore, these data suggest that pharmacological approaches targeted to the specific
or combinated use of glutamatergic and dopaminergic treatments may be effective and should
be explored (for a review see, Smith-Wilcke & Clauw, 2010).
Finally, recent investigations postulate that FM could be characterized by an alteration of brain
connectivity among different brain networks (Cifre et al., 2012; Napadow et al., 2010). It has
been documented that chronic pain produces a disruption in the default mode network (DMN;
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Baliki et al., 2008). Evidence coming from neuroimaging studies reported increased resting
state connectivity between insula and other brain networks such as the DMN in FM patients.
This connectivity pattern was highly and positively correlated with spontaneous pain
(Napadow et al., 2010). In fact, when a sample of patients underwent to an acupuncture
treatment aimed to diminish pain perception, the degree of connectivity between insula and
DMN was also decreased leading to consider resting state connectivity as an objective marker
to assess pain in FM (Napadow et al., 2012). Other studies have confirmed the presence of an
altered connectivity pattern among brain regions belonging to pain processing network in FM
during rest (Cifre et al., 2012). Indeed, such alteration might be due to slow temporal summa‐
tion effects evoked by C-fiber pain (Craggs et al., 2012).
3. Neural correlates of cognitive dysfunction in fibromyalgia
3.1. Cognitive complaints in FM
It has been suggested that FM syndrome is characterized by an abnormal processing of
information in the central nervous system (Montoya et al., 2005; Okijufi et al., 2002) affecting
the response to somatosensory stimulation (e.g., painful signals) but also to information
belonging to other modalities (e.g., visual, auditory, etc). Several studies indicate that apart
from pain and other physical symptoms, cognitive failures are referred by these patients as
one of the most important complaints (recently denominated as fibrofog; Glass, 2009; Williams
et al., 2011), leading to produce even greater functional impact than pain itself (Arnold et al.,
2008; Glass et al., 2005). Thus, the incidence rate for memory and concentration difficulties
exceeds 90% in FM, being significantly higher that one ocurred in other chronic pain conditions
(Arnold et al., 2008; Mease et al., 2008). Additionally, self-reports of patients support the
presence of a higher number of cognitive problems than patients suffering from other chronic
pain syndromes (Katz et al., 2004), affecting several cognitive domains (Williams et al., 2011).
For example, memory complaints of FM patients were positively correlated with the objective
perfomance obtained in tasks which set in motion memory resources (Glass et al., 2005).
Moreover, these cognitive difficulties manifest persistently in many of daily activities involv‐
ing the allocation of attentional control resources such as to remember that they have to call
someone the next day or to inhibit thoughts that do not allow them to develop other concurrent
daily tasks. Experimental evidence confirms that attention, concentration, episodic memory
and verbal fluency are impaired in FM (Glass, 2009) showing that such difficulties in the
processing of information constitute a very disruptive symptom for patients who have FM,
worsening its quality of life and leading to consider it as an independent symptom (Schmidt-
Wilcke et al., 2010).
3.2. Neuropsychological and behavioural data on cognitive dysfunction in FM
Since the beginning of the past decade growing objective evidence based mainly on neuro‐
psychological studies has shown real and significant impairments of cognitive functions in FM
(Glass & Park, 2001; Park et al., 2001). First attempts to characterize dyscognition in FM
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reported deficits in the two declarative memory systems related to the explicit recall of
information, episodic and semantic memory. Experimental data revealed poor performance
on both standardized (Grace et al., 1999) and non-standarized episodic memory tests (Landro
et al., 1997; Grisart et al., 2002). Semantic memory problems have also been documented. FM
group showed lower ability for accessing to stored general knowledge than control group
when patients were asked to report as many words as they could say starting with a given
letter (for example, ‘p’) and belonging to a specific category (for example, ‘fruits and vegeta‐
bles’) (Landro et al., 1997; Park et al., 2001). Along with verbal fluency difficulties, a decrease
in naming speed (Leavitt et al., 2008) and speed processing (Veldhuijzen et al., 2012) was also
found in FM patients. However, those results are not unequivocal since some studies failed to
find differences in cognitive function between patients and healthy control participants (Suhr,
2003). This variability could be related to the lack of previous systematic and detailed research,
suggesting that cognitive impairment in FM patients is not generalized; rather is specific-
process dependent.
Recent data have suggested that findings on cognitive dysfunction in FM are particularly solid
when patients have to deal with tasks demanding for both executive control and working
memory resources (Ambrose et al., 2012; Glass, 2010). Impairments in those domains seem to
be the key to explain a great part of the cognitive dysfunction in FM. Executive functions (EF)
refer to those mechanisms that allow the regulation of both behaviour and other cognitive
processes to achieve a specific objective (Muñoz-Céspedes and Tirapu, 2001). Within this
theoretical frame, working memory is defined as the support system of those EF aimed to
temporarily hold in mind and manage with a variable amount of information (Baddeley,
2000). Thus, working memory dysfunctions have also been seen in FM (Luerding et al., 2008).
It has been also observed that patients perform poorly in a variety of tasks involving the
allocation of executive control resources to alternate between cognitive sets (Verdejo-García
et al., 2009) and to make emotional decisions (Verdejo-García et al., 2009; Walteros et al.,
2011) or to face with a task-switching test (Glass, 2006). Tests commonly used to study those
executive function processes are Wisconsin Card Sorting Test (WCST) and the Iowa Gambling
Task (IGT). Several studies using the Paced Auditory Serial Attention Test (PASAT) have
detected a diminished perfomance in FM individuals compared to controls (Leavitt & Katz,
2006; Munguía-Izquierdo et al., 2008). Other working memory components like response
inhibition are also suggested to be impaired in FM (Correa et al., 2011). Very similar results
have been found during the performance in those tests with a high degree of ecological validity
(Test of Everyday Attention, TEA) that includes everyday attentional tasks (Dick et al., 2008).
Working memory components measured by TEA were impaired in FM, especially when
stimuli competition had to be solved. In this sense, the fact that attentional control difficulties
become more evident during distraction (derived from a situation of stimuli competition) has
lead to consider it as a key point to better understand cognitive dysfunction in FM (Leavitt &
Katz, 2006). It was proposed that failures to inhibit competing stimulation might be an
explanation for this difficulty; due to FM patients show hypersensitivity to process information
coming from any sensorial modality (Geisser et al., 2008). Such general distractibility could be
translated into an attentional orientation towards any type of task-irrelevant stimuli (González
et al., 2010) leading to difficulties to focalize attention on relevant information. However, recent
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data derived from the use of cognitive inhibition tests indicate that patients with FM do not
show a specific problem in such processes (Veldhuijzen et al., 2012).
Although the body of research on cognitive dysfunction in FM has strongly grown in recent
years, there are still several unexplored issues in this field of knowledge that should be
investigated such as the delimitation of the specific cognitive mechanisms that are altered in
these patients. For instance, it is accepted that working memory abilities are impaired in FM,
but are different components (e.g., temporal holding of information, inhibition, manage with
two concurrent tasks, etc) characterizing working memory equally affected? Kim and collea‐
gues (2012) have indicated that memory is selectively impaired in FM showing the possible
existence of a memory dissociation. Data coming from neuropsychological assessments reveal
that whereas visuospatial memory abilities are dysfunctional, verbal memory is quite unaf‐
fected. Following a similar reasoning, several studies postulate that cognitive dysfunction in
FM is restricted to those cognitive mechanisms based on controlled processes (Grisart et al.,
2002). However, the presence of a generalized hypervigilance response in FM (Carrillo de la
Peña et al., 2006) seems to be under the control of automatic processes, rather than controlled
ones (Crombez et al., 2005). Moreover, recent data have demonstrated a reduced performance
of patients with FM during an implicit memory task (Duschek et al., 2013). It is the first direct
evidence of cognitive disruption associated with processes non-dependent from conscious and
controlled resources in FM. Finally, several comorbid symptoms of FM (e.g., anxiety, depres‐
sion, sleep disturbances, medication, pain, etc) have been associated with a worsening of
cognitive dysfunction. Although the impact of affective symptomatology (anxiety and
depression) and sleep problems on the cognitive dysfunction in FM might be important, these
variables do not entirely explain it (Park et al., 2001; Dick et al., 2008). However, the negative
impact of both chronic and acute pain seems to be very robust. When this variable is controlled
FM patients show a marked impairment in tasks involving different cognitive domains (Glass
et al., 2011; Reyes del Paso et al., 2012; Verdejo-García et al., 2009). Additionally, level of self-
reported pain is correlated with cognitive performance in FM (Glass et al., 2005) and it has
been highlighted as a mediating variable to explain deficits in self-regulatory processes in these
patients (Solberg et al., 2010). Therefore, the role of pain on cognitive disturbances is considered
as quite relevant. Nevertheless, the neurocognitive mechanisms by means pain interferes on
patient’s cognitive function are still unknown.
3.3. Brain activity related to cognitive dysfunction in FM
As it was previously indicated, accumulated evidence supports the presence of clear objective
impairments in cognitive function of patients with FM. Cognitive dysfunctional pattern
associated with FM (i.e., executive control deficits, working memory failures and declarative
memory difficulties) points out to the existence of an altered neural substrate, presumably at
least within prefrontal regions, such as inferior prefrontal cortex (IPC), MPFC or ACC along
with their connexions with temporal and parietal regions (Glass, 2010; Glass et al., 2011).
Although studies focused on these neural mechanisms underlying dysfunctional cognitive
processes in FM are still surprisingly scarce, new findings cast some light on the possible
altered neurocognitive mechanisms. In this sense, neuroimaging investigations have repeat‐
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edly showed increased haemodynamic activity at prefrontal regions (i.e., dorsolateral pre‐
frontal cortex –DLPFC-, ventromedial prefrontal –VMPFC- cortex and ACC) during tasks
involving working memory and executive control processes (Bunge et al., 2000; Dagher et al.,
1999). Moreover, Altamura and coworkers (2007) have highlighted that the right allocation of
working memory resources to accomplish a given task depends on prefrontal regions.
Specific data related to FM patients, have found that working memory performance in FM
patients was highly and positively correlated with grey matter values within MPFC and ACC,
showing that a decrease of grey matter volume within those prefrontal regions is associated
with working memory deficits in FM (Luerding et al., 2008). Additionally, recent functional
neuroimaging investigations have revealed diminished activations in cortical regions belong‐
ing to the inhibition network, such as ACC, mid-cingulated cortex (MCC) and motor process‐
ing areas in patients with FM during the performance in a simple go/no-go task (Glass et al.,
2011). At the same time, inefficient activations were detected within insular cortex and IFG
when patients had to perform on the mentioned response motor inhibition task. It has been
suggested that such effects might be explained via either a greater brain recruitment of cortical
compensatory regions different from those involved in response inhibition network. Extend‐
ing such findings, our research group has tried to characterize cognitive inhibition mecha‐
nisms, as part of the altered working memory functions, in patients with FM. Patients showed
both enhanced P450 amplitudes and brain activations within IFG in response to an emotional
Stroop task (Mercado et al., in press). More in detail, symptom-related words were the kind
of stimulation that elicited both the greater frontal P450 amplitudes and the higher IFG
activations as compared to rest of stimuli (i.e., general negative-arousing, positive-arousing
and neutral words; see Figures 2 and 3). This abnormally enhanced brain activity suggests the
presence of a specific difficulty in cognitive inhibition in FM patients (under conditions
intimately linked with the core concerns of their disease). However, such supplementary
recruitment of neural resources by means same cortical areas only allow them to achieve a
comparable behavioural performance to healthy control group during the cognitive inhibition
task. These results are in contradiction with those coming from behavioural studies indicating
intact cognitive inhibition abilities in FM (Veldhuijzen et al., 2012). A tentative explanation
could be related to the idea that brain activity techniques might be more sensitive to detect
subtle dysfunctions than behavioural measures alone such as often occurs in FM patients
(Glass et al., 2011). Other functional neuroimaging studies have showed that working memory
dysfunction (measured through a n-back task) in FM are related to a reduction of neural
activity not only at prefrontal regions but also within inferior parietal cortex (IPC) (Seo et al.,
2012). It suggests that a different neural activation pattern of the frontoparietal memory
network could be explaining, at least partially, cognitive impairments in FM. Diminished early
ERP activity of FM patients during a 2-back task has been also detected at inferior parietal sites,
Suggesting that problems associated with the early storage of information might be attribut‐
able to analtered functioning of parietal areas (Mercado et al.,in preparation). On the other
hand, some investigations have indicated the presence of differences associated with the
hippocampus activity between patients and healthy control participants (Emad et al., 2008).



























Figure 2. Grand averages of P450 component corresponding to Fibromyalgia (FM) and Healthy control (HC) partici‐
pants in response to FM symptoms (SF), negative-arousing (A-), positive-arousing (A+) and neutral (N) stimuli. Scales
and polarity are shown at F4. 3D maps show topographical distribution of the P450 component. Red areas reflect high
activity.
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Figure 3. rIFG activity from the emotional Stroop task for patients with fibromyalgia (FM) and healthy control partici‐
pants (HC). Right side shows sLORETA solutions to non-parametric randomization tests on P450 component. Coronal
brain view in MNI305 template, sliced through the region of maximum activity, is illustrated. Left side shows mean
rIFG activity for FM patients and HC participants across the four word categories: FM symptoms (SF), negative-arous‐
ing (A-), positive-arousing (A+) and neutral (N) stimuli. Error bars reflect standard errors. Black line represent rIFG activ‐
ity for FM patients and, grey line, for HC participants.
As mentioned before, cognitive dysfunctions and pain processing may rely on partially
overlapping regions in FM patients. As a consequence of this, resources taken up by pain
processing may not be available for executive functioning (Glass et al., 2011). Pain level of
patients might contribute to this effect over cognition. Neuroimaging techiques represent an
opportunity to advance in the comprehension of FM and further studies should be done to
delimitate deficits in order to develop better diagnostic and classification criteria of FM patients
and to better design neuropsychological interventions oriented to increase their quality of life.
4. Genetics in fibromyalgia: Pain and cognition
Genetic predisposition is likely to be an important factor in the development of FM as
suggested by several familial studies (Buskila et al., 1996, 2007; Arnold et al., 2004). These
studies found that first-degree relatives of patients with FM had lower pain threshold than
controls and were 8.5 times more likely to develop FM than relatives of patients with rheu‐
matoid arthritis. The studies also indicated that the relatives of FM patients are more likely to
suffer from comorbidities commonly seen in FM, such as mood disorders, irritable bowel
syndrome (IBS), temporomandibular disorder (TMD) and headache (Ablin et al., 2008; Buskila
et al., 1996, 2007). Identifying the genes responsible for this genetic contribution to risk should
provide a better understanding of the complex mechanisms underlying FM and other chronic
pain diseases. In recent years, attempts have been made to identify the genes involved in FM
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using candidate gene genetic association studies, which look for differences in the frequency
of different polymorphisms between cases and controls, or with a quantifiable trait. The
majority of such candidates have been genes involved in catecholaminergic or serotonergic
neurotransmission, including receptors and transporters for dopamine, serotonin, norepi‐
nephrine, and epinephrine, as well as the catabolic enzymes catechol-O-methyltransferase
(COMT).
Next we will review, in outline, the main findings made on genes associated with FM. The
most widely studied gene to date is Catechol-O-Methyltransferase (COMT), which degrades
catecholamines such as dopamine, noradrenaline and adrenalin that are involved in various
physiological functions including mood, cognition and stress response (Belfer and Segal,
2011). In particular, a single nucleotide polymorphism (SNP), (rs4680), has received a great
deal of attention due its functional implications (Zubieta et al., 2003). This polymorphism
causes a substitution from a valina (Val) to a methionine (Met) at amino acid position 158
(Val158Met), leading to a three to four fold reduced activity of the COMT enzyme (Lotta et al.,
1995). In 2005, Diatchenko and colleagues described three very common haplotypes consisting
of four SNPs (rs6269, rs 4633, rs4818 and rs4680-Val158Met) accounting for 96% of all haplo‐
types observed in human populations (Diatchenko et al., 2005). They identified them as low
(LPS), average (APS) and high (HPS) pain sensitivity haplotypes, and they found a correlation
with much more profound change in COMT activity (up to 20-fold difference).
The met/met genotype of the COMT Val158Met polymorphism has been associated with higher
sensitivity in response to pain stimuli and the number of tender points in FM (Cohen et al.,
2009) as well as with a high risk for the development of FM (García-Fructuoso et al., 2006;
Barbosa et al., 2012). Recently, Martínez-Jauand and colleagues (2013) have shown that the
HPS-APS haplotypes are more frequent in FM patients than in healthy controls and that FM
patients who possess those genetic combinations displayed an increased sensitivity to
experimental pain. These results are in accordance with previous reports showing a strong
association between the HPS haplotype and high score on the Fibromyalgia Impact Question‐
naire (Vargas-Alarcón et al., 2007). These haplotypes might be associated with increased risk
of developing chronic pain disorders (Diatchenko et al., 2005). These data suggest that a
decrease of COMT activity might contribute to the maintenance of pain symptoms in FM, and
might play a significant role in classifying FM patients (Martínez-Jauand et al., 2013).
COMT variants moderate not only pain but also maladaptive coping processes in patients with
FM. Finan and colleagues (2010 and 2011) demonstrated that Met158 allele homozygotes
experience more pain in days when pain catastrophizing and pain attention scores were
elevated, and a greater decline in positive affect on days when pain was elevated. These
findings support the role of COMT and catecholamines in affective reactivity to pain, and in
pain-related cognition pathways in patients with FM. A recent study has proposed that the
Val158Met can play a relevant role in phenotypic expression of FM. They showed that women
with FM and Met/Met genotype had more severe psychological and functional impact scores
than those with the Val/Val genotype, although the differences were not significant (Desmeules
et al., 2012). More recently, Fernández de las Peñas and colleagues (2012) have shown that FM
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patients with Met/Met genotype exhibit higher disability, anxiety and depression than those
with Val/Val and Val/Met genotype.
As indicated above, cognitive dysfunction has been considered as one of the most disturbing
symptoms, apart from pain, in patients with FM. Neuropsychological investigations have
suggested that executive control and working memory impairments seem to be the key to
explain a great part of this cognitive dysfunction in FM (Glass, 2010) and it points out to the
existence of an altered neural substrate, presumably within prefrontal regions, such as inferior
prefrontal cortex (IPFC), MPFC or ACC (Glass et al., 2011). In this context, it has been shown
that more than 60% of released dopamine is metabolized by COMT in the frontal cortex
(Karoum et al., 1994), and that the Val158Met polymorphism affects working memory and
executive functions in healthy population (Bruder et al., 2005) and some mental disorders such
as schizophrenia (Diaz-Asper et al., 2006; Hosak, 2007). Therefore, COMT may be a good
candidate for the study of cognitive impairment in patients with FM.
The endogenous serotonergic system is comprised of the neurotransmitter serotonin (5-HT),
multiple serotonin receptors (5-HT2A, 5-HT3A, 5-HT3B) and the serotonin transporter (5-
HTT). This system is a key contributor to both depression and pain in FM. In fact, serotonin is
decreased in FM, and selective serotonin reuptake inhibitors have some efficacy in FM (Gupta
and Silman, 2004). Despite the complexity of the serotonergic pathway, research has mainly
focused on a limited number of genes. Offenbaecher and colleagues (1999) analyzed the
genotypes of the promoter region of the serotonin transporter gene (5-HTT) in patients with
FM and healthy controls. A significantly higher frequency of the S/S genotype of the serotonin
transporter promoter region was found in FM as compared to healthy participants. The S/S
subgroup exhibited higher mean levels of depression and psychological distress. It was
suggested that these results support the notion of an altered serotonin metabolism in at least
a subgroup of patients with FM (Buskila et al., 2007). These findings were subsequently
confirmed by a study analyzing Palestinian Arabs and Israeli Jews (Cohen et al., 2002).
However, the study in other candidate genes within the serotonergic system failed to demon‐
strate a significant difference in the frequency of the polymorphism among FM patients and
controls (Bondy et al., 1999; Frank et al., 2004; Matsuda et al., 2010).
The dopaminergic system has also been the target of extensive study in search of the genetic
factors related to FM. Dopamine is a crucial neurotransmitter involved in multiple activities
including pain transmission and endogenous analgesia (Wood, 2008). A single nucleotide
polymorphism (Ser9Gly) in the dopamine-D3 receptor gene predicts changes in pain threshold
in FM patients but not in healthy subjects (Potvin et al., 2009). In the FM group, the Ser9Gly
polymorphism was a predictor of decreased thermal pain threshold and diffuse noxious
inhibitory control (DNIC) efficacy (Potvin et al., 2009). Polymorphisms in the dopamine
receptor 4 (DRD4) gene has also been associated with FM. Buskila and colleagues (2004)
reported a significant decrease in the frequency of the 7 repeated allele in exon III of the D4
receptor gene in FM patients, who also demonstrated an association between this polymor‐
phism and the low novelty seeking personality trait. This was considered consistent with the
personality profile of FM patients, who scored high on anxiety related personality traits and
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low on novelty or sensation seeking. In a study of 384 subjects with DRD4 polymorphism,
allele 4 was the most common, occurring in 279 of the 384 subjects (Treister et al., 2009).
However, there was no change in cold tolerance, cold perception, cold pain threshold, or heat
pain intensity in those subjects compared to subjects with allele 2 or allele 7 (Treister et al.,
2009). Dopamine D2 receptor (DRD2) is implicated in different cognitive processes and brain
disorder, and polymorphisms in this gene affect gene expression, splicing, and neuronal
activity during working memory (Zhang et al., 2007). This has been demonstrated in patients
with schizophrenia, whose presence relatively increased density of DRD2 (Laruelle, 1998).
Curiously, it has also been observed an increased sensitivity or density of dopamine D2
receptors (DRD2) in FM patients (Malt et al., 2003). Preliminary results in our research group
found a significant relationship between promoter SNP (rs12364283) in DRD2 and working
memory functioning in FM patients. Specifically, we found significant differences during the
performance in both Spatial Span (forward sequence) and n-back tasks. Heterozygotes (TC)-
FM patients had a lower performance compared to TC-HC in both Spatial Span and n-back
tasks. They also perform worse than homozygotes TT-FM patients but only in the Spatial Span
task (Gómez-Esquer et al., 2012). Our results suggest that DRD2 could be playing an important
role in working memory functioning in FM patients and support the implication of dopami‐
nergic pathways in the cognitive symptoms of FM.
Another candidate gene is the β2-adrenergic receptor (ADRB2). It mediates physiologic
responses such as vasodilation and bronchial smooth-muscle relaxation, and represents a
connection between the sympathetic nervous system and the immune system (Small et al.,
2003; Catapano & Mangi, 2007). Alterations in the ADRB2 function have been implicated in
several psychiatric and psychological disorders, including those associated with chronic pain
(Lee et al., 2012). Vargas-Alarcón and colleagues (2009) reported that having the AC haplotype
of the two SNPs (rs1042713 and rs1042714) was associated with an increased risk for suffering
FM among Mexican and Spanish individuals. Recently, it has been published the first study
to demonstrate ADRB2 polymorphism-related differences in intracellular cyclic Adenosine
Monophosphate (cAMP) levels in FM Peripheral Blood Mononuclear Cells (PBMC), before
and after ADRB2 stimulation. These findings suggest that ADRB2 polymorphisms may
influence the response to a variety of β-adrenergic ligands and may help to explain some
differences in responsiveness of FM subgroups to the adrenergic agonist medication currently
approved for FM treatment (Xiao et al., 2011).
Finally, we will briefly discuss about SCN9A, a gene that encodes sodium channel in dorsal
root ganglia (DRG). A consistent line of investigation suggests that autonomic nervous system
dysfunction may explain the multi-system features of FM. In this context, DRG play a key role
in pain perception and sodium channels located in DRG act as molecular gatekeepers of pain
detection at peripheral nociceptors. Mutations in this gene have caused severe pain disorders
and congenital insensitivity to pain in families, thus demonstrating a critical role in pain
processing (Drenth and Waxman, 2007). In FM, Vargas Alarcón and colleagues (2012) dem‐
onstrated that, in Mexican women, the frequency of rs6754031 polymorphism of SCN9A was
significantly different between FM patients and healthy controls. Interestingly, patients with
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GG genotype had higher Fibromyalgia Impact Questionnaire (FIQ) scores than patients with
the GT or TT genotype. These results show that there is an association between the rs6754031
polymorphism and the risk of developing FM as well as the FIQ score. This association raises
the possibility that some patients with severe FM may have a DRG sodium channelopathy
(Vargas-Alarcón et al., 2012). However, further investigation will be necessary in other ethnic
groups with a large sample size to verify this observation.
Despite the large number of studies examining the potential contribution of the candidate gene
polymorphism to FM susceptibility, many studies have produced conflicting results (Potvin
et al., 2010; Frank et al., 2004; Gursoy, 2002). The explanation for these results could be that
individual studies based on small sample sizes have insufficient power to detect positive
associations and they are incapable of demonstrating the absence of such association. Recently,
Lee and colleagues (2012) have conducted a systematic meta-analysis of seventeen candidate
genes and over 35 polymorphisms were identified in studies on FM susceptibility. This meta-
analysis demonstrates that the 5-HT2A receptor 102T/C polymorphism confers susceptibility
to FM. In contrast, no association was found between the 5-HTTLPR S/L allele, COMT
Val158Met, and susceptibility to FM. However, the authors were aware of the limitations of
their meta-analysis since both the number of the studies and the number of the subjects
included in such studies were too small. This may have not enough power to explore the
association between the candidate gene polymorphism and FM. They could not perform the
ethnic-specific meta-analysis to detect associations in ethnic groups due to limited data. They
have not been able either to examine whether the candidate gene polymorphisms are associ‐
ated with clinical features of FM (Lee et al., 2012). Therefore, additional research including
large numbers of patients and controls is required to conclude the association of the candidate
gene polymorphisms with FM. Another approach being made lately to identify genetic factors
involved in FM is the use of a large-scale candidate gene approach (Smith et al., 2012). This is
the largest candidate genes association study of the FM to date, analyzing 3,295 SNPs corre‐
sponding to > 350 genes involved in the biological pathways relevant to nociception, inflam‐
mation, and mood. This work observed significant differences in allele frequencies between
cases and controls for several novel genes: GABRB3 (in the promoter region of the GABA-A
β receptor gene), TAAR1 (trace amine-associated receptor 1), GBP1 (guanylate binding protein
1), RGS4 (regulator of G-protein signaling 4), CNR1 (CB-1 cannabinoid receptor gene), and
GRIA4 (AMPA ionotropic glutamate receptor 4 subunit). Three of these genes, TAAR1, RGS4,
and CNRI play roles in the modulation of analgesic pathways (Smith et al., 2012). Variation in
these 4 replicated genes may serve as a basis for the development of new diagnostic ap‐
proaches, and the products of these genes may contribute to the pathophysiology of FM and
represent potential target for therapeutic actions.
5. Conclusions and future directions
Evidence from FM investigations indicates that psychoneurobiological dysfunctions play a
relevant role in the pathophysiology of this multifactorial and still not fully understood
syndrome. Specifically, it was suggested that abnormalities in central brain mechanisms are
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crucial in the understanding of chronic pain in FM, having little relevance the involvement of
peripheral processing systems. Mechanisms of central sensitization and those involving
descending inhibitory pathways, along with abnormalities in neurotransmission regulatory
processes, seem to underlie patient’s manifestations of hyperalgesia and allodynia, among
other pain-related symptoms. Experimental findings also have demonstrated that both
morphological and functional brain changes are related to widespread and diffuse pain and
cognitive symptoms suffered by patients with FM.
On the other hand, patients with FM are characterized by the presence of difficulties in the
processing of information reporting that it constitutes a very disruptive symptom in their
everyday functioning. Cognitive disturbances are mainly related to both executive functions
and working memory processes. Neuroimaging investigations have found abnormal activity
within prefrontal and parietal regions when patients had to face a demanding task of executive
control resources. However, many researchers are trying to answer an important question in
order to advance in the knowledge on FM. Can cognitive dysfunction in FM be considered as
a primary symptom like abnormal pain perception or, by contrast, is it a direct consequence
of the structural or functional changes produced by pain? Based on present findings, cognitive
dysfunctions and pain processing seem to share brain networks (prefrontal, supplementary
motor regions and parietal cortices) and as a consequence of this, resources taken up by pain
processing may not be available for executive functioning. Thus, performance in those tasks,
which need a recruitment of working memory resources from the frontoparietal brain network
to be correctly completed, would be very poor in FM. Neuroimaging techniques represent an
opportunity to advance in the comprehension of pain and cognition interactions in FM and
further studies should be done to explore such deficits and their interrelations.
Current data support the statement that FM constitutes a real syndrome characterized by the
existence of multiple changes into the brain. Future investigations should be projected to
extend these findings and to establish comprehensive explanations about: 1) cerebral mecha‐
nisms that provoke those changes, 2) its consequences on the functional state of patients and,
3) if brain changes constitute a reversible or permanent condition in the brain of FM patients.
In this sense, different therapeutic approaches targeted to reverse such changes in the brain
(e.g., pharmacological treatments, neuropsychological interventions, transcraneal magnetic
stimulation, etc) may be effective and should be explored. The investigation about different
genetic polymorphisms is a promising approach that may also help to improve the compre‐
hension of the pathogenesis of this multifactorial and intriguing syndrome.
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